1-3 of 3
Kerry McDonald Taylor
Close
Sort by
Journal Articles

Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).

Susan Branford, Timothy Hughes, Steven Stylian, Anthony P. Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Robyn Rodwell, Nancy Guzzo-Pernell, Deb Taylor, Jenny Larson, Rachel Koelmayer, Alvin Milner, Kevin Lynch, Kerry McDonald Taylor
Journal: Blood
Blood (2006) 108 (11): 2142.
https://doi.org/10.1182/blood.V108.11.2142.2142
Published: 2006
Journal Articles

Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML.

John Francis Seymour, MBBS, PhD, Andrew Grigg, MB BS, John Reynolds, Ph D, Anthony P. Schwarer, MB BS PhD, Richard Hermann, MB BS, Kerry McDonald Taylor, MB BS, Kenneth Francis Bradstock, MB BS PhD, Anthony K. Mills, MB BS, Rachel Koelmeyer, BSc, Kevin Lynch, Timothy Hughes, MBBS MD
Journal: Blood
Blood (2006) 108 (11): 2147.
https://doi.org/10.1182/blood.V108.11.2147.2147
Published: 2006
Journal Articles

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

John Francis Seymour, MBBS FRACP, Andrew Grigg, MBBS FRACP, John Reynolds, Jane Matthews, Anthony P. Schwarer, MBBS FRACP, Richard Herrmann, MBBS FRACP, Kerry McDonald Taylor, MBBS FRACP, Mark S. Hertzberg, MBBS FRACP, Anthony Mills, MBBS FRACP, Nancy Guzzo-Pernell, Michael Copeman, MBBS FRACP, Kevin Lynch, MBBS, Timothy Hughes, MBBS FRACP
Journal: Blood
Blood (2004) 104 (11): 1020.
https://doi.org/10.1182/blood.V104.11.1020.1020
Published: 2004